We need to address this problem.

As Members of Congress, we typically speak about treating disease in sound bites.

And the problem I have is if we grant exclusivity, we are essentially giving the pharmaceutical free rein to charge whatever it wants during that time period.

There clearly needs to be some balance between the exclusivity and the cost savings.

I seriously question whether a lengthy exclusivity will achieve the kind of savings we all hope to see.

I share your concern about the seemingly ever increasing cost of drugs and its impact on both patients and on the health care system as a whole.

I believe that there are many factors to encouraging and ensuring robust investment in medicines.

Let me echo what you said about the hearing and the value of it. I totally agree.

Cures and cutting-edge medicines are of no value if their high costs put them out of reach of the patients who need them.

We believe, and we have made a recommendation along these lines, you can take the elements from that instrument...

For many years, there has been a lot of discussion about how we move our health care system into one of quality and efficiency.

I am amazed by how much variation exists in the care provided in the post-acute setting.